Amlodipine/rosuvastatin

Drug Profile

Amlodipine/rosuvastatin

Alternative Names: GSK-3074477; Rosuvastatin/amlodipine

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihypertensives; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 01 Jul 2014 GlaxoSmithKline completes a phase I trial in Hypertension (In volunteers) in Singapore (NCT02075619)
  • 01 Mar 2014 Phase-I clinical trials in Hypertension (In volunteers) in Singapore (PO) (NCT02075619)
  • 27 Feb 2014 Preclinical trials in Hypertension in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top